-
Categories
-
Tags
21 CFR 820.30 21 CFR Part 820 510(k) 510(k) Contents and Format 510(k) format and content 510(k) Requirements 510(k)s 510k 510k In Person Seminar 510k LIVE seminar 510k LIVE Webinar 510K Seminar 510k submission Adverse Event Reporting Adverse Event Reporting Systems Advertising and Promotion AERS AIMDD ANDA Animal Drugs Asian Country Big Data Biocompatibility Biologics Biosimilars BLA CAPA CDRH CE Mark China Complaint Complaint Handling David Lim Design Control Dr. David Lim Drugs EMA EN ISO 13485:2012 EN ISO 14971:2012 EU EU Marketing Authorization Application (MAA) FDA FDA 510(k) FDA 510(k) Seminar: Best Practices for 510(k) Preparation FDA Guidance FDA Inspection FDA-Regulated Industry FMEA Fundamentals of Regulatory Affairs Generics Global Compliance Seminar Hatch-Waxman Act Healthcare Industry Hong Kong Human Drug IDE IND ISO 13485 ISO 14155 IVDD IVDs Japan Korea Laws and Regulations LIVE 510(k) Webinar LIVE Online Seminar LIVE Webinar MAA to EMA in EU Mandatory Adverse Event Reporting Marketing Approvals for Generic Medicines MDD MDR Medical Device Medical Device Reporting Medical Devices Medicine NDA Opioid Abuse Opioid Addiction Opioids Pain Management Paragraph IV Certification Patent Patent Exclusivity PMA PMA Drafting Seminar PMA Seminar PMAs Postmarket Surveillance Postmarket Vigilance Pre-submission Premarket Approval Premarket Notification Q-Submission QSR Quality Risk Management Quality System Regulation Recorded Recorded 510k Seminar Recorded PMA Seminar reference listed drug Regulatory Affairs Regulatory Doctor Regulatory Plan Regulatory Plan/Strategy Regulatory Requirements Regulatory Strategy Risk Analysis Risk Management RLD Safety Signals Social Media Marketing Social Media Practice Social Media Practices SOPs Submission and Clearance | Global Compliance Seminar substantial equivalence UDI Unique Device Identification Unique Device Identifier US FDA US FDA 510(k) US RAC Exam Writing an Effective SOP
LIVE Online Seminar
Best Practices for Communicating and Interacting with FDA Reviewers
- Date: December 8, 2016
- This seminar recurs tri-monthly on second Thursdays.
- Time: 08:00 AM PST | 11:00 AM EST
- Duration: 60 Minutes
About the Seminar
This seminar (webinar) is intended to help those in pharmaceutical and medical device industry involved in interacting and communicating with the health authorities. In particular, this seminar will discuss best practices for communicating, interacting and negotiating with FDA reviewers before and during the review process.
In this 60-min presentation, the speaker will guide you through the details of what is best in exercising your judgement and discretion while communicating and interacting with the FDA reviewers.
About the Areas to Be Discussed
- FD&C Act and its implementing regulations
- FDA reviewer’s duties and responsibilities
- Types and characteristics of FDA reviewers
- Working with (in)experienced reviewers: issues, challenges and solutions
- Applying emotional intelligence and negotiation skills
- Dealing with changing scope of information request
- Dealing with when the reviewer is not making his/her position clear
- Understanding and analyzing an FDA reviewer’s position: views and comments
- Responding to the FDA reviewer’s questions and additional information
- Handling when interaction and communication are not going anywhere
- Dealing with when retaliatory actions by the reviewer are perceived
- Draft guidance, issued March 5, 2013, entitled “Types of Communication During the Review of Medical Device Submissions.”
- Practical, actionable, and sustainable strategies/solutions
About the Intended Attendee(s)
- Regulatory affairs in pharmaceutical and medical device industry
- Quality
- Legal counsel
- Compliance officers
- Consultants
- Regulatory agency personnel
- Anyone interested in the subject
About the Seminar Speaker
Dr. David Lim, Ph.D., RAC, ASQ-CQA. Dr. Lim is President and Principal of Regulatory Doctor. Dr. Lim frequently presents global laws, regulations, rules, guidance, and regulatory requirements applicable to medical products. In particular, Dr. Lim provides seminars on various areas and focused-topics in regulatory affairs, clinical affairs, quality and regulatory compliance.
Recently, Dr. Lim developed 510(k) templates ready for use compliant with e-Copy and RTA policy. In addition, Dr. Lim developed the industry’s first PMA seminar series delivered online, helping global regulatory affairs professionals become a PMA pro. Dr. Lim developed FDA inspection checklists for drug and medical device manufacturers based on his analysis of FDA inspectional observations cited in 483s for the past seven years. Dr. Lim provides his feedback to regulatory agency (e.g., US FDA) through public comments and also served as a panel member during the FDA’s transparency public meeting in 2009. Dr. Lim contributes to the Regulatory Affairs Professional Society (RAPS) as an author. Dr. Lim leads and directs all research projects including, but not limited to, pharmacovigilance, medical device reporting, recalls and patient safety signals being conducted at the Regulatory Doctor.
Registration Options
- Option 1: you may send your “request to purchase” by email to Global Compliance Seminar
- Option 2: you may request an invoice by email to Global Compliance Seminar
- Option 3: you may purchase online below using a credit card or PayPal.
LIVE (one attendee): $199
Recorded: $249
LIVE (≤ 4 attendees): $699
LIVE (≥ 5 attendees): $899
LIVE & Recorded: $299
LIVE Online Seminar
Best Practices for Communicating and Interacting with FDA Reviewers
- Date: December 8, 2016
- This seminar recurs tri-monthly on second Thursdays.
- Time: 08:00 AM PST | 11:00 AM EST
- Duration: 60 Minutes
About the Seminar
This seminar (webinar) is intended to help those in pharmaceutical and medical device industry involved in interacting and communicating with the health authorities. In particular, this seminar will discuss best practices for communicating, interacting and negotiating with FDA reviewers before and during the review process.
In this 60-min presentation, the speaker will guide you through the details of what is best in exercising your judgement and discretion while communicating and interacting with the FDA reviewers.
About the Areas to Be Discussed
- FD&C Act and its implementing regulations
- FDA reviewer’s duties and responsibilities
- Types and characteristics of FDA reviewers
- Working with (in)experienced reviewers: issues, challenges and solutions
- Applying emotional intelligence and negotiation skills
- Dealing with changing scope of information request
- Dealing with when the reviewer is not making his/her position clear
- Understanding and analyzing an FDA reviewer’s position: views and comments
- Responding to the FDA reviewer’s questions and additional information
- Handling when interaction and communication are not going anywhere
- Dealing with when retaliatory actions by the reviewer are perceived
- Draft guidance, issued March 5, 2013, entitled “Types of Communication During the Review of Medical Device Submissions.”
- Practical, actionable, and sustainable strategies/solutions
About the Intended Attendee(s)
- Regulatory affairs in pharmaceutical and medical device industry
- Quality
- Legal counsel
- Compliance officers
- Consultants
- Regulatory agency personnel
- Anyone interested in the subject
About the Seminar Speaker
Dr. David Lim, Ph.D., RAC, ASQ-CQA. Dr. Lim is President and Principal of Regulatory Doctor. Dr. Lim frequently presents global laws, regulations, rules, guidance, and regulatory requirements applicable to medical products. In particular, Dr. Lim provides seminars on various areas and focused-topics in regulatory affairs, clinical affairs, quality and regulatory compliance.
Recently, Dr. Lim developed 510(k) templates ready for use compliant with e-Copy and RTA policy. In addition, Dr. Lim developed the industry’s first PMA seminar series delivered online, helping global regulatory affairs professionals become a PMA pro. Dr. Lim developed FDA inspection checklists for drug and medical device manufacturers based on his analysis of FDA inspectional observations cited in 483s for the past seven years. Dr. Lim provides his feedback to regulatory agency (e.g., US FDA) through public comments and also served as a panel member during the FDA’s transparency public meeting in 2009. Dr. Lim contributes to the Regulatory Affairs Professional Society (RAPS) as an author. Dr. Lim leads and directs all research projects including, but not limited to, pharmacovigilance, medical device reporting, recalls and patient safety signals being conducted at the Regulatory Doctor.
Registration Options
- Option 1: you may send your “request to purchase” by email to Global Compliance Seminar
- Option 2: you may request an invoice by email to Global Compliance Seminar
- Option 3: you may purchase online below using a credit card or PayPal.
LIVE (one attendee): $199
Recorded: $249
LIVE (≤ 4 attendees): $699
LIVE (≥ 5 attendees): $899
LIVE & Recorded: $299
LIVE Online Seminar
Best Practices for Communicating and Interacting with FDA Reviewers
- Date: December 8, 2016
- This seminar recurs tri-monthly on second Thursdays.
- Time: 08:00 AM PST | 11:00 AM EST
- Duration: 60 Minutes
About the Seminar
This seminar (webinar) is intended to help those in pharmaceutical and medical device industry involved in interacting and communicating with the health authorities. In particular, this seminar will discuss best practices for communicating, interacting and negotiating with FDA reviewers before and during the review process.
In this 60-min presentation, the speaker will guide you through the details of what is best in exercising your judgement and discretion while communicating and interacting with the FDA reviewers.
About the Areas to Be Discussed
- FD&C Act and its implementing regulations
- FDA reviewer’s duties and responsibilities
- Types and characteristics of FDA reviewers
- Working with (in)experienced reviewers: issues, challenges and solutions
- Applying emotional intelligence and negotiation skills
- Dealing with changing scope of information request
- Dealing with when the reviewer is not making his/her position clear
- Understanding and analyzing an FDA reviewer’s position: views and comments
- Responding to the FDA reviewer’s questions and additional information
- Handling when interaction and communication are not going anywhere
- Dealing with when retaliatory actions by the reviewer are perceived
- Draft guidance, issued March 5, 2013, entitled “Types of Communication During the Review of Medical Device Submissions.”
- Practical, actionable, and sustainable strategies/solutions
About the Intended Attendee(s)
- Regulatory affairs in pharmaceutical and medical device industry
- Quality
- Legal counsel
- Compliance officers
- Consultants
- Regulatory agency personnel
- Anyone interested in the subject
About the Seminar Speaker
Dr. David Lim, Ph.D., RAC, ASQ-CQA. Dr. Lim is President and Principal of Regulatory Doctor. Dr. Lim frequently presents global laws, regulations, rules, guidance, and regulatory requirements applicable to medical products. In particular, Dr. Lim provides seminars on various areas and focused-topics in regulatory affairs, clinical affairs, quality and regulatory compliance.
Recently, Dr. Lim developed 510(k) templates ready for use compliant with e-Copy and RTA policy. In addition, Dr. Lim developed the industry’s first PMA seminar series delivered online, helping global regulatory affairs professionals become a PMA pro. Dr. Lim developed FDA inspection checklists for drug and medical device manufacturers based on his analysis of FDA inspectional observations cited in 483s for the past seven years. Dr. Lim provides his feedback to regulatory agency (e.g., US FDA) through public comments and also served as a panel member during the FDA’s transparency public meeting in 2009. Dr. Lim contributes to the Regulatory Affairs Professional Society (RAPS) as an author. Dr. Lim leads and directs all research projects including, but not limited to, pharmacovigilance, medical device reporting, recalls and patient safety signals being conducted at the Regulatory Doctor.
Registration Options
- Option 1: you may send your “request to purchase” by email to Global Compliance Seminar
- Option 2: you may request an invoice by email to Global Compliance Seminar
- Option 3: you may purchase online below using a credit card or PayPal.
LIVE (one attendee): $199
Recorded: $249
LIVE (≤ 4 attendees): $699
LIVE (≥ 5 attendees): $899
LIVE & Recorded: $299
LIVE Online Seminar
Best Practices for Communicating and Interacting with FDA Reviewers
- Date: December 8, 2016
- This seminar recurs tri-monthly on second Thursdays.
- Time: 08:00 AM PST | 11:00 AM EST
- Duration: 60 Minutes
About the Seminar
This seminar (webinar) is intended to help those in pharmaceutical and medical device industry involved in interacting and communicating with the health authorities. In particular, this seminar will discuss best practices for communicating, interacting and negotiating with FDA reviewers before and during the review process.
In this 60-min presentation, the speaker will guide you through the details of what is best in exercising your judgement and discretion while communicating and interacting with the FDA reviewers.
About the Areas to Be Discussed
- FD&C Act and its implementing regulations
- FDA reviewer’s duties and responsibilities
- Types and characteristics of FDA reviewers
- Working with (in)experienced reviewers: issues, challenges and solutions
- Applying emotional intelligence and negotiation skills
- Dealing with changing scope of information request
- Dealing with when the reviewer is not making his/her position clear
- Understanding and analyzing an FDA reviewer’s position: views and comments
- Responding to the FDA reviewer’s questions and additional information
- Handling when interaction and communication are not going anywhere
- Dealing with when retaliatory actions by the reviewer are perceived
- Draft guidance, issued March 5, 2013, entitled “Types of Communication During the Review of Medical Device Submissions.”
- Practical, actionable, and sustainable strategies/solutions
About the Intended Attendee(s)
- Regulatory affairs in pharmaceutical and medical device industry
- Quality
- Legal counsel
- Compliance officers
- Consultants
- Regulatory agency personnel
- Anyone interested in the subject
About the Seminar Speaker
Dr. David Lim, Ph.D., RAC, ASQ-CQA. Dr. Lim is President and Principal of Regulatory Doctor. Dr. Lim frequently presents global laws, regulations, rules, guidance, and regulatory requirements applicable to medical products. In particular, Dr. Lim provides seminars on various areas and focused-topics in regulatory affairs, clinical affairs, quality and regulatory compliance.
Recently, Dr. Lim developed 510(k) templates ready for use compliant with e-Copy and RTA policy. In addition, Dr. Lim developed the industry’s first PMA seminar series delivered online, helping global regulatory affairs professionals become a PMA pro. Dr. Lim developed FDA inspection checklists for drug and medical device manufacturers based on his analysis of FDA inspectional observations cited in 483s for the past seven years. Dr. Lim provides his feedback to regulatory agency (e.g., US FDA) through public comments and also served as a panel member during the FDA’s transparency public meeting in 2009. Dr. Lim contributes to the Regulatory Affairs Professional Society (RAPS) as an author. Dr. Lim leads and directs all research projects including, but not limited to, pharmacovigilance, medical device reporting, recalls and patient safety signals being conducted at the Regulatory Doctor.
Registration Options
- Option 1: you may send your “request to purchase” by email to Global Compliance Seminar
- Option 2: you may request an invoice by email to Global Compliance Seminar
- Option 3: you may purchase online below using a credit card or PayPal.
LIVE (one attendee): $199
Recorded: $249
LIVE (≤ 4 attendees): $699
LIVE (≥ 5 attendees): $899
LIVE & Recorded: $299
LIVE Online Seminar
Best Practices for Communicating and Interacting with FDA Reviewers
- Date: December 8, 2016
- This seminar recurs tri-monthly on second Thursdays.
- Time: 08:00 AM PST | 11:00 AM EST
- Duration: 60 Minutes
About the Seminar
This seminar (webinar) is intended to help those in pharmaceutical and medical device industry involved in interacting and communicating with the health authorities. In particular, this seminar will discuss best practices for communicating, interacting and negotiating with FDA reviewers before and during the review process.
In this 60-min presentation, the speaker will guide you through the details of what is best in exercising your judgement and discretion while communicating and interacting with the FDA reviewers.
About the Areas to Be Discussed
- FD&C Act and its implementing regulations
- FDA reviewer’s duties and responsibilities
- Types and characteristics of FDA reviewers
- Working with (in)experienced reviewers: issues, challenges and solutions
- Applying emotional intelligence and negotiation skills
- Dealing with changing scope of information request
- Dealing with when the reviewer is not making his/her position clear
- Understanding and analyzing an FDA reviewer’s position: views and comments
- Responding to the FDA reviewer’s questions and additional information
- Handling when interaction and communication are not going anywhere
- Dealing with when retaliatory actions by the reviewer are perceived
- Draft guidance, issued March 5, 2013, entitled “Types of Communication During the Review of Medical Device Submissions.”
- Practical, actionable, and sustainable strategies/solutions
About the Intended Attendee(s)
- Regulatory affairs in pharmaceutical and medical device industry
- Quality
- Legal counsel
- Compliance officers
- Consultants
- Regulatory agency personnel
- Anyone interested in the subject
About the Seminar Speaker
Dr. David Lim, Ph.D., RAC, ASQ-CQA. Dr. Lim is President and Principal of Regulatory Doctor. Dr. Lim frequently presents global laws, regulations, rules, guidance, and regulatory requirements applicable to medical products. In particular, Dr. Lim provides seminars on various areas and focused-topics in regulatory affairs, clinical affairs, quality and regulatory compliance.
Recently, Dr. Lim developed 510(k) templates ready for use compliant with e-Copy and RTA policy. In addition, Dr. Lim developed the industry’s first PMA seminar series delivered online, helping global regulatory affairs professionals become a PMA pro. Dr. Lim developed FDA inspection checklists for drug and medical device manufacturers based on his analysis of FDA inspectional observations cited in 483s for the past seven years. Dr. Lim provides his feedback to regulatory agency (e.g., US FDA) through public comments and also served as a panel member during the FDA’s transparency public meeting in 2009. Dr. Lim contributes to the Regulatory Affairs Professional Society (RAPS) as an author. Dr. Lim leads and directs all research projects including, but not limited to, pharmacovigilance, medical device reporting, recalls and patient safety signals being conducted at the Regulatory Doctor.
Registration Options
- Option 1: you may send your “request to purchase” by email to Global Compliance Seminar
- Option 2: you may request an invoice by email to Global Compliance Seminar
- Option 3: you may purchase online below using a credit card or PayPal.
LIVE (one attendee): $199
Recorded: $249
LIVE (≤ 4 attendees): $699
LIVE (≥ 5 attendees): $899
LIVE & Recorded: $299
LIVE Online Seminar
Best Practices for Communicating and Interacting with FDA Reviewers
- Date: December 8, 2016
- This seminar recurs tri-monthly on second Thursdays.
- Time: 08:00 AM PST | 11:00 AM EST
- Duration: 60 Minutes
About the Seminar
This seminar (webinar) is intended to help those in pharmaceutical and medical device industry involved in interacting and communicating with the health authorities. In particular, this seminar will discuss best practices for communicating, interacting and negotiating with FDA reviewers before and during the review process.
In this 60-min presentation, the speaker will guide you through the details of what is best in exercising your judgement and discretion while communicating and interacting with the FDA reviewers.
About the Areas to Be Discussed
- FD&C Act and its implementing regulations
- FDA reviewer’s duties and responsibilities
- Types and characteristics of FDA reviewers
- Working with (in)experienced reviewers: issues, challenges and solutions
- Applying emotional intelligence and negotiation skills
- Dealing with changing scope of information request
- Dealing with when the reviewer is not making his/her position clear
- Understanding and analyzing an FDA reviewer’s position: views and comments
- Responding to the FDA reviewer’s questions and additional information
- Handling when interaction and communication are not going anywhere
- Dealing with when retaliatory actions by the reviewer are perceived
- Draft guidance, issued March 5, 2013, entitled “Types of Communication During the Review of Medical Device Submissions.”
- Practical, actionable, and sustainable strategies/solutions
About the Intended Attendee(s)
- Regulatory affairs in pharmaceutical and medical device industry
- Quality
- Legal counsel
- Compliance officers
- Consultants
- Regulatory agency personnel
- Anyone interested in the subject
About the Seminar Speaker
Dr. David Lim, Ph.D., RAC, ASQ-CQA. Dr. Lim is President and Principal of Regulatory Doctor. Dr. Lim frequently presents global laws, regulations, rules, guidance, and regulatory requirements applicable to medical products. In particular, Dr. Lim provides seminars on various areas and focused-topics in regulatory affairs, clinical affairs, quality and regulatory compliance.
Recently, Dr. Lim developed 510(k) templates ready for use compliant with e-Copy and RTA policy. In addition, Dr. Lim developed the industry’s first PMA seminar series delivered online, helping global regulatory affairs professionals become a PMA pro. Dr. Lim developed FDA inspection checklists for drug and medical device manufacturers based on his analysis of FDA inspectional observations cited in 483s for the past seven years. Dr. Lim provides his feedback to regulatory agency (e.g., US FDA) through public comments and also served as a panel member during the FDA’s transparency public meeting in 2009. Dr. Lim contributes to the Regulatory Affairs Professional Society (RAPS) as an author. Dr. Lim leads and directs all research projects including, but not limited to, pharmacovigilance, medical device reporting, recalls and patient safety signals being conducted at the Regulatory Doctor.
Registration Options
- Option 1: you may send your “request to purchase” by email to Global Compliance Seminar
- Option 2: you may request an invoice by email to Global Compliance Seminar
- Option 3: you may purchase online below using a credit card or PayPal.
LIVE (one attendee): $199
Recorded: $249
LIVE (≤ 4 attendees): $699
LIVE (≥ 5 attendees): $899
LIVE & Recorded: $299
LIVE Online Seminar
Best Practices for Communicating and Interacting with FDA Reviewers
- Date: December 8, 2016
- This seminar recurs tri-monthly on second Thursdays.
- Time: 08:00 AM PST | 11:00 AM EST
- Duration: 60 Minutes
About the Seminar
This seminar (webinar) is intended to help those in pharmaceutical and medical device industry involved in interacting and communicating with the health authorities. In particular, this seminar will discuss best practices for communicating, interacting and negotiating with FDA reviewers before and during the review process.
In this 60-min presentation, the speaker will guide you through the details of what is best in exercising your judgement and discretion while communicating and interacting with the FDA reviewers.
About the Areas to Be Discussed
- FD&C Act and its implementing regulations
- FDA reviewer’s duties and responsibilities
- Types and characteristics of FDA reviewers
- Working with (in)experienced reviewers: issues, challenges and solutions
- Applying emotional intelligence and negotiation skills
- Dealing with changing scope of information request
- Dealing with when the reviewer is not making his/her position clear
- Understanding and analyzing an FDA reviewer’s position: views and comments
- Responding to the FDA reviewer’s questions and additional information
- Handling when interaction and communication are not going anywhere
- Dealing with when retaliatory actions by the reviewer are perceived
- Draft guidance, issued March 5, 2013, entitled “Types of Communication During the Review of Medical Device Submissions.”
- Practical, actionable, and sustainable strategies/solutions
About the Intended Attendee(s)
- Regulatory affairs in pharmaceutical and medical device industry
- Quality
- Legal counsel
- Compliance officers
- Consultants
- Regulatory agency personnel
- Anyone interested in the subject
About the Seminar Speaker
Dr. David Lim, Ph.D., RAC, ASQ-CQA. Dr. Lim is President and Principal of Regulatory Doctor. Dr. Lim frequently presents global laws, regulations, rules, guidance, and regulatory requirements applicable to medical products. In particular, Dr. Lim provides seminars on various areas and focused-topics in regulatory affairs, clinical affairs, quality and regulatory compliance.
Recently, Dr. Lim developed 510(k) templates ready for use compliant with e-Copy and RTA policy. In addition, Dr. Lim developed the industry’s first PMA seminar series delivered online, helping global regulatory affairs professionals become a PMA pro. Dr. Lim developed FDA inspection checklists for drug and medical device manufacturers based on his analysis of FDA inspectional observations cited in 483s for the past seven years. Dr. Lim provides his feedback to regulatory agency (e.g., US FDA) through public comments and also served as a panel member during the FDA’s transparency public meeting in 2009. Dr. Lim contributes to the Regulatory Affairs Professional Society (RAPS) as an author. Dr. Lim leads and directs all research projects including, but not limited to, pharmacovigilance, medical device reporting, recalls and patient safety signals being conducted at the Regulatory Doctor.
Registration Options
- Option 1: you may send your “request to purchase” by email to Global Compliance Seminar
- Option 2: you may request an invoice by email to Global Compliance Seminar
- Option 3: you may purchase online below using a credit card or PayPal.
LIVE (one attendee): $199
Recorded: $249
LIVE (≤ 4 attendees): $699
LIVE (≥ 5 attendees): $899
LIVE & Recorded: $299
LIVE Online Seminar
Best Practices for Communicating and Interacting with FDA Reviewers
- Date: December 8, 2016
- This seminar recurs tri-monthly on second Thursdays.
- Time: 08:00 AM PST | 11:00 AM EST
- Duration: 60 Minutes
About the Seminar
This seminar (webinar) is intended to help those in pharmaceutical and medical device industry involved in interacting and communicating with the health authorities. In particular, this seminar will discuss best practices for communicating, interacting and negotiating with FDA reviewers before and during the review process.
In this 60-min presentation, the speaker will guide you through the details of what is best in exercising your judgement and discretion while communicating and interacting with the FDA reviewers.
About the Areas to Be Discussed
- FD&C Act and its implementing regulations
- FDA reviewer’s duties and responsibilities
- Types and characteristics of FDA reviewers
- Working with (in)experienced reviewers: issues, challenges and solutions
- Applying emotional intelligence and negotiation skills
- Dealing with changing scope of information request
- Dealing with when the reviewer is not making his/her position clear
- Understanding and analyzing an FDA reviewer’s position: views and comments
- Responding to the FDA reviewer’s questions and additional information
- Handling when interaction and communication are not going anywhere
- Dealing with when retaliatory actions by the reviewer are perceived
- Draft guidance, issued March 5, 2013, entitled “Types of Communication During the Review of Medical Device Submissions.”
- Practical, actionable, and sustainable strategies/solutions
About the Intended Attendee(s)
- Regulatory affairs in pharmaceutical and medical device industry
- Quality
- Legal counsel
- Compliance officers
- Consultants
- Regulatory agency personnel
- Anyone interested in the subject
About the Seminar Speaker
Dr. David Lim, Ph.D., RAC, ASQ-CQA. Dr. Lim is President and Principal of Regulatory Doctor. Dr. Lim frequently presents global laws, regulations, rules, guidance, and regulatory requirements applicable to medical products. In particular, Dr. Lim provides seminars on various areas and focused-topics in regulatory affairs, clinical affairs, quality and regulatory compliance.
Recently, Dr. Lim developed 510(k) templates ready for use compliant with e-Copy and RTA policy. In addition, Dr. Lim developed the industry’s first PMA seminar series delivered online, helping global regulatory affairs professionals become a PMA pro. Dr. Lim developed FDA inspection checklists for drug and medical device manufacturers based on his analysis of FDA inspectional observations cited in 483s for the past seven years. Dr. Lim provides his feedback to regulatory agency (e.g., US FDA) through public comments and also served as a panel member during the FDA’s transparency public meeting in 2009. Dr. Lim contributes to the Regulatory Affairs Professional Society (RAPS) as an author. Dr. Lim leads and directs all research projects including, but not limited to, pharmacovigilance, medical device reporting, recalls and patient safety signals being conducted at the Regulatory Doctor.
Registration Options
- Option 1: you may send your “request to purchase” by email to Global Compliance Seminar
- Option 2: you may request an invoice by email to Global Compliance Seminar
- Option 3: you may purchase online below using a credit card or PayPal.
LIVE (one attendee): $199
Recorded: $249
LIVE (≤ 4 attendees): $699
LIVE (≥ 5 attendees): $899
LIVE & Recorded: $299
LIVE Online Seminar
Best Practices for Communicating and Interacting with FDA Reviewers
- Date: December 8, 2016
- This seminar recurs tri-monthly on second Thursdays.
- Time: 08:00 AM PST | 11:00 AM EST
- Duration: 60 Minutes
About the Seminar
This seminar (webinar) is intended to help those in pharmaceutical and medical device industry involved in interacting and communicating with the health authorities. In particular, this seminar will discuss best practices for communicating, interacting and negotiating with FDA reviewers before and during the review process.
In this 60-min presentation, the speaker will guide you through the details of what is best in exercising your judgement and discretion while communicating and interacting with the FDA reviewers.
About the Areas to Be Discussed
- FD&C Act and its implementing regulations
- FDA reviewer’s duties and responsibilities
- Types and characteristics of FDA reviewers
- Working with (in)experienced reviewers: issues, challenges and solutions
- Applying emotional intelligence and negotiation skills
- Dealing with changing scope of information request
- Dealing with when the reviewer is not making his/her position clear
- Understanding and analyzing an FDA reviewer’s position: views and comments
- Responding to the FDA reviewer’s questions and additional information
- Handling when interaction and communication are not going anywhere
- Dealing with when retaliatory actions by the reviewer are perceived
- Draft guidance, issued March 5, 2013, entitled “Types of Communication During the Review of Medical Device Submissions.”
- Practical, actionable, and sustainable strategies/solutions
About the Intended Attendee(s)
- Regulatory affairs in pharmaceutical and medical device industry
- Quality
- Legal counsel
- Compliance officers
- Consultants
- Regulatory agency personnel
- Anyone interested in the subject
About the Seminar Speaker
Dr. David Lim, Ph.D., RAC, ASQ-CQA. Dr. Lim is President and Principal of Regulatory Doctor. Dr. Lim frequently presents global laws, regulations, rules, guidance, and regulatory requirements applicable to medical products. In particular, Dr. Lim provides seminars on various areas and focused-topics in regulatory affairs, clinical affairs, quality and regulatory compliance.
Recently, Dr. Lim developed 510(k) templates ready for use compliant with e-Copy and RTA policy. In addition, Dr. Lim developed the industry’s first PMA seminar series delivered online, helping global regulatory affairs professionals become a PMA pro. Dr. Lim developed FDA inspection checklists for drug and medical device manufacturers based on his analysis of FDA inspectional observations cited in 483s for the past seven years. Dr. Lim provides his feedback to regulatory agency (e.g., US FDA) through public comments and also served as a panel member during the FDA’s transparency public meeting in 2009. Dr. Lim contributes to the Regulatory Affairs Professional Society (RAPS) as an author. Dr. Lim leads and directs all research projects including, but not limited to, pharmacovigilance, medical device reporting, recalls and patient safety signals being conducted at the Regulatory Doctor.
Registration Options
- Option 1: you may send your “request to purchase” by email to Global Compliance Seminar
- Option 2: you may request an invoice by email to Global Compliance Seminar
- Option 3: you may purchase online below using a credit card or PayPal.
LIVE (one attendee): $199
Recorded: $249
LIVE (≤ 4 attendees): $699
LIVE (≥ 5 attendees): $899
LIVE & Recorded: $299
LIVE Online Seminar
Best Practices for Communicating and Interacting with FDA Reviewers
- Date: December 8, 2016
- This seminar recurs tri-monthly on second Thursdays.
- Time: 08:00 AM PST | 11:00 AM EST
- Duration: 60 Minutes
About the Seminar
This seminar (webinar) is intended to help those in pharmaceutical and medical device industry involved in interacting and communicating with the health authorities. In particular, this seminar will discuss best practices for communicating, interacting and negotiating with FDA reviewers before and during the review process.
In this 60-min presentation, the speaker will guide you through the details of what is best in exercising your judgement and discretion while communicating and interacting with the FDA reviewers.
About the Areas to Be Discussed
- FD&C Act and its implementing regulations
- FDA reviewer’s duties and responsibilities
- Types and characteristics of FDA reviewers
- Working with (in)experienced reviewers: issues, challenges and solutions
- Applying emotional intelligence and negotiation skills
- Dealing with changing scope of information request
- Dealing with when the reviewer is not making his/her position clear
- Understanding and analyzing an FDA reviewer’s position: views and comments
- Responding to the FDA reviewer’s questions and additional information
- Handling when interaction and communication are not going anywhere
- Dealing with when retaliatory actions by the reviewer are perceived
- Draft guidance, issued March 5, 2013, entitled “Types of Communication During the Review of Medical Device Submissions.”
- Practical, actionable, and sustainable strategies/solutions
About the Intended Attendee(s)
- Regulatory affairs in pharmaceutical and medical device industry
- Quality
- Legal counsel
- Compliance officers
- Consultants
- Regulatory agency personnel
- Anyone interested in the subject
About the Seminar Speaker
Dr. David Lim, Ph.D., RAC, ASQ-CQA. Dr. Lim is President and Principal of Regulatory Doctor. Dr. Lim frequently presents global laws, regulations, rules, guidance, and regulatory requirements applicable to medical products. In particular, Dr. Lim provides seminars on various areas and focused-topics in regulatory affairs, clinical affairs, quality and regulatory compliance.
Recently, Dr. Lim developed 510(k) templates ready for use compliant with e-Copy and RTA policy. In addition, Dr. Lim developed the industry’s first PMA seminar series delivered online, helping global regulatory affairs professionals become a PMA pro. Dr. Lim developed FDA inspection checklists for drug and medical device manufacturers based on his analysis of FDA inspectional observations cited in 483s for the past seven years. Dr. Lim provides his feedback to regulatory agency (e.g., US FDA) through public comments and also served as a panel member during the FDA’s transparency public meeting in 2009. Dr. Lim contributes to the Regulatory Affairs Professional Society (RAPS) as an author. Dr. Lim leads and directs all research projects including, but not limited to, pharmacovigilance, medical device reporting, recalls and patient safety signals being conducted at the Regulatory Doctor.
Registration Options
- Option 1: you may send your “request to purchase” by email to Global Compliance Seminar
- Option 2: you may request an invoice by email to Global Compliance Seminar
- Option 3: you may purchase online below using a credit card or PayPal.
LIVE (one attendee): $199
Recorded: $249
LIVE (≤ 4 attendees): $699
LIVE (≥ 5 attendees): $899
LIVE & Recorded: $299